Bruker takes majority stake in organ-on-a-chip maker MIMETAS
What's the deal? Bruker CorporationDealroom has a profile for this one. Try Dealroom → has taken a majority stake in MIMETAS B.V., a Dutch developer of organ-on-a-chip platforms and human tissue and disease models for drug discovery. The deal expands Bruker's post-genomic tools into microphysiological systems (MPS), also known as new approach methodologies (NAMs). Financial terms were not disclosed.
What does MIMETAS do? It builds scalable organ-on-a-chip platforms that let researchers study disease mechanisms and compound responses in perfused, human-relevant systems. Its OrganoPlate platform pairs a standard microtiter-plate format with membrane-free microfluidic tissue cultures, supporting imaging, automated handling, and higher-throughput workflows.
What's the rationale? Bruker plans to combine MIMETAS capabilities with its own technologies in proteomics, metabolomics, NMR, preclinical imaging, and spatial biology. The companies aim to build integrated product and service workflows linking human model systems with Bruker's tools for molecular and cellular characterisation.
What's the endgame? The MIMETAS portfolio spans the OrganoPlate platform, OrganoReady tissue and organoid products, supporting instruments, and contract research services. Together, the two companies plan to serve drug discovery, development, and preclinical testing.
"Human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates," said Frank H. Laukien, president and chief executive officer of Bruker.
The signal: Laukien said he expects humanised microphysiological systems to be "increasingly adopted in drug discovery, development and preclinical testing." The bet reflects growing interest in human-relevant model systems as an alternative approach to studying disease and testing compounds.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
